Key clinical point: The interleukin-1 alpha inhibitor improved both pain and lesion count in patients regardless of prior treatment with an antitumor necrosis factor agent.
Major finding: Cleared lesions and improved pain in more than 60% of patients who received it.
Study details: The 12-week proof-of-concept study comprised 42 patients.
Disclosures: XBiotech is developing the drug and sponsored the study. Dr. Gottlieb was an investigator and designed the protocol, but did not receive compensation for her work.
REPORTING FROM AAD 2019